NASDAQ · ASRT

Assertio Holdings, Inc.

$23.50 +$0.02 (+0.09%) 1D
Charting by TradingView

Key Metrics

$63.78M
Market cap
—
P/E · TTM
$102.16M
Revenue · TTM
−$35.69M
Net income
EPS · TTM $-5.60
Dividend yield —
Free cash flow —
Beta · 1Y 0.62
EBITDA · TTM −$8.88M
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 4
    The stock moved +17.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 4
  • Mar 24
    The stock moved +17.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 24

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$63.78M
Enterprise value$31.46M
Shares outstanding6.4M
52-wk range$0.65 – $23.50
Avg volume · 20D1.1M
Net cash $32.32M
Book value / share$11.86
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Assertio Holdings, Inc.
IPO dateNov 5, 1997
Employees30

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S0.62
P/FCF—
EV/EBITDA—
EV/Sales0.31
Graham №—

Profitability

Gross —
Operating -34.7%
Net -34.9%
FCF —
ROE / ROIC -36.3% · -82.4%

Financial Health

Current ratio1.82
Quick ratio1.57
Debt / equity0.52
Debt / EBITDA -4.42
Net cash $32.32M
Working capital$75.28M

Cash Flow · TTM

Operating CF −$7.08M
Capex —
Free cash flow —
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

-4.1
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings